KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $760.0 million.

  • GoodRx Holdings' Non-Current Assets rose 438.79% to $760.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 421.81%. This contributed to the annual value of $728.8 million for FY2024, which is 178.8% up from last year.
  • GoodRx Holdings' Non-Current Assets amounted to $760.0 million in Q3 2025, which was up 438.79% from $768.1 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year Non-Current Assets high stood at $772.8 million for Q2 2023, and its period low was $387.6 million during Q1 2021.
  • Its 5-year average for Non-Current Assets is $669.2 million, with a median of $716.0 million in 2023.
  • In the last 5 years, GoodRx Holdings' Non-Current Assets skyrocketed by 5388.96% in 2021 and then plummeted by 621.27% in 2024.
  • Over the past 5 years, GoodRx Holdings' Non-Current Assets (Quarter) stood at $518.8 million in 2021, then soared by 32.03% to $684.9 million in 2022, then grew by 4.54% to $716.0 million in 2023, then grew by 1.79% to $728.8 million in 2024, then rose by 4.28% to $760.0 million in 2025.
  • Its Non-Current Assets stands at $760.0 million for Q3 2025, versus $768.1 million for Q2 2025 and $755.1 million for Q1 2025.